Xilio Therapeutics, Inc. (XLO) Stock Analysis & Investment Frameworks
Xilio Therapeutics, Inc. (XLO) stock analysis on Invetso. Review Xilio Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Xilio Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Xilio Therapeutics, Inc. Key Financial Metrics
- Market Cap: $56.19M
- Revenue: $43.77M
- ROE: -50.77%
- ROIC: -25.82%
- Dividend Yield: N/A
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Xilio Therapeutics, Inc. Investment Frameworks
Invetso analyzes Xilio Therapeutics, Inc. (XLO) across the following frameworks:
- Xilio Therapeutics, Inc. 10Y Growth Potential
- Xilio Therapeutics, Inc. Scenario Analysis
- Xilio Therapeutics, Inc. Risks & Opportunities
- Xilio Therapeutics, Inc. Economic Moat
- Xilio Therapeutics, Inc. Business Model
- Xilio Therapeutics, Inc. Management
- Xilio Therapeutics, Inc. SWOT Analysis
- Xilio Therapeutics, Inc. Porter's 5 Forces
- Xilio Therapeutics, Inc. PESTLE Analysis
- Xilio Therapeutics, Inc. ESG Analysis